欧美少妇一区二区三区在线观看,综合日韩欧美在线,亚洲精品欧美另类,亚洲第一成人一区二区,午夜精品欧美视频,欧美综合_区二区三区,亚洲免费成人在线观看,亚洲麻豆精品久久,91精品国产综合久久久久久久色,女主播午夜福利视频,亚洲熟女少妇一区二区视频,九九九九九九精品免费,亚洲蜜臀av一区二区三区,国内免费精品一区二区三区,亚洲毛片免费电影,国产精品久久久久性,亚洲一区二区三区国产区,日韩欧美人妻区一区二区,午夜一区二区三区黄色,亚洲欧美综合人成野草,激情欧美日韩综合,亚洲精品十八禁一区二区三区,中文字幕欧美一区

       2023年，賽國生物再次取得依科賽/ExCell Bio一級授權(quán)代理書。

      依科賽生物(ExCell Bio)創(chuàng)立于2013年，以“加快生命科技應(yīng)用，造福百姓健康”為使命，致力于解決生物醫(yī)藥卡脖子、實現(xiàn)關(guān)鍵原料國產(chǎn)化，現(xiàn)已成為中國生物醫(yī)藥上游核心原材料的領(lǐng)軍企業(yè)之一。公司是國家高新技術(shù)企業(yè)，國家級專精特新小巨人企業(yè)，中國首家國際血清行業(yè)協(xié)會（ISIA）會員單位，江蘇省生物制藥、細胞治療等領(lǐng)域用CD無血清培養(yǎng)基工程研究中心。

      公司當前聚焦無血清培養(yǎng)基、胎牛血清和鑒定試劑等三大產(chǎn)品板塊，為生物藥、細胞與基因治療、基礎(chǔ)科學(xué)研究客戶提供國際品質(zhì)的產(chǎn)品與服務(wù)。公司依托國際化和專業(yè)化的研發(fā)技術(shù)團隊、質(zhì)量和生產(chǎn)團隊以及商業(yè)化團隊，持續(xù)創(chuàng)新，追求卓越，在不斷優(yōu)化產(chǎn)品性能的同時，確保可靠的質(zhì)量和穩(wěn)定的供應(yīng)，全面賦能生物醫(yī)藥產(chǎn)業(yè)的快速健康發(fā)展，打造細胞培養(yǎng)“中國芯”產(chǎn)品。

     公司目前已服務(wù)超過10,000家客戶遍布高校、研究所、醫(yī)院、生物制藥、基因測序等企業(yè)客戶。在上海、北京、廣州、深圳、香港等全國主要城市設(shè)有管理和營銷中心，并在美國、澳大利亞和烏拉圭設(shè)有分公司。

      In 2023, Saiguo Biotech once again obtained the first-level authorization letter of ExCell Bio.

      Founded in 2013, with the mission of "accelerating the application of life science and technology and benefiting the health of the people", ExCell Bio is committed to solving the neck of biomedicine and realizing the localization of key raw materials, and has now become one of the leading enterprises in China's biomedical upstream core raw materials. The company is a national high-tech enterprise, a national specialized and special new small giant enterprise, China's first member unit of the International Serum Industry Association (ISIA), and a CD serum-free media engineering research center in the fields of biopharmaceuticals and cell therapy in Jiangsu Province.

      The company currently focuses on three major product segments, including serum-free culture media, fetal bovine serum and identification reagents, and provides international quality products and services for customers in biological drugs, cell and gene therapy, and basic scientific research. Relying on the international and professional R & D technical team, quality and production team and commercialization team, the company continues to innovate, pursues excellence, ensures reliable quality and stable supply while continuously optimizing product performance, fully empowers the rapid and healthy development of the biomedical industry, and creates cell culture "Chinese core" products.

     At present, the company has served more than 10,000 customers in universities, research institutes, hospitals, biopharmaceuticals, gene sequencing and other enterprise customers. It has management and marketing centers in major cities such as Shanghai, Beijing, Guangzhou, Shenzhen and Hong Kong, and branches in the United States, Australia and Uruguay.

【2023/1/3 12:40:02】